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ABSTRACT
PURPOSE: MicroRNAs (miRNAs) are small regulatory RNAs that post
transcriptionally modify mRNAs and control gene expression. Circulating miRNAs are
significantly altered following a single session of exercise, however the effects of
exercise training on the circulating miRNA profile is unclear. Therefore, the purpose of
the present study was to determine the effects of endurance exercise training on the
abundance of targeted circulating miRNAs and the association of changes in miRNA
levels with concomitant changes in cardiometabolic traits, in a subsample of adults from
the HERITAGE Family Study.
METHODS: This exploratory analysis examined 20 previously sedentary adults from
the HERITAGE Family Study who completed 20 weeks of endurance exercise training.
miRNAs were isolated from serum samples taken at baseline and post-training. The
expression of 84 miRNAs related to cardiovascular disease and development was
measured at both time points by performing RT-qPCR on the Human Cardiovascular
Disease miScript miRNA PCR array (Qiagen, Hilden, Germany). Fold change was
calculated as 2-∆∆Ct using the global geometric mean signal of all detected microRNAs as
the normalizer value. Paired t-tests were used to examine the effects of exercise training
on individual miRNA levels.
RESULTS: Exercise training resulted in nominally significant down-regulation of five
miRNAs (miR-155-5p, let-7b-5p, let-7e-5p, miR-486-5p, and miR-7-5p) compared to
baseline (Fold change: 0.33-0.76, p=0.01-0.04). Change in miR-486-5p expression was
ii

moderately correlated with change in small high-density lipoprotein particle
concentration (r = -0.55, p=0.01) and change in low-density lipoprotein particle size
(r=0.53, p=0.01). Additionally, change in miR-7-5p was correlated with change in very
low-density lipoprotein particle concentrations (r = -0.47, p=0.04).
CONCLUSIONS: Exercise training altered the expression of specific miRNAs
associated with cardiovascular disease, which was related to concomitant changes in the
plasma lipoprotein profile. MiRNAs therefore represent a potential mechanism that
partially mediates the beneficial effects of exercise on cardiometabolic traits. Further
research is needed to understand the complete effects of exercise on the circulating
miRNA profile.
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CHAPTER 1
INTRODUCTION

MicroRNAs (miRNAs) are small non-coding regulatory RNAs that control gene
expression via post-transcriptional modification of messenger RNA (mRNA).1, 2
MiRNAs silence mRNAs through two distinct mechanisms: mRNA degradation or
repression of mRNA translation.2 Over 2,500 different miRNAs have been identified in
humans, and despite accounting for an estimated 1-5% of the human genome, miRNAs
are estimated to regulate greater than 30% of protein coding genes.2-4 MiRNAs are
transported into circulation within exosomes, protein complexes, or microvesicles.2, 5 The
transport of miRNAs in these complexes prevents their breakdown and allows miRNAs
to circulate to and act on target cells throughout the body.1, 2 Thus, circulating miRNAs
represent a novel biomarker for diseases such as cancer and cardiovascular disease
(CVD).2, 6, 7
Altered circulating miRNA profiles have been identified in patients with many
different diseases, including different forms of cancer, diabetes, and forms of CVD.8, 9
Additionally, Zampetaki et al.10 found that baseline miRNA profiles were associated with
incident myocardial infarction over ten years in an elderly cohort, suggesting that
miRNAs can also be used to predict future disease. MiRNAs have also been associated
with many steps during the progression towards atherosclerosis, and associated with
acute myocardial infarction, coronary artery disease, and unstable angina.7, 11
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Additionally, miRNAs play an essential role in many biological processes such as
angiogenesis, mitochondrial metabolism, and cardiac/skeletal muscle hypertrophy.12-14
These pathways have implications beyond disease risk reduction and are associated with
adaptations often found following exercise training. Indeed, miRNAs have recently been
shown to correlate with cardiovascular adaptation to exercise,15 demonstrating an active
functional role of miRNAs in human physiology. The associations of miRNAs with
disease, as well as the physiological effects of miRNAs on multiple biological pathways,
demonstrate the potential clinical relevance of circulating miRNAs as biomarkers of
disease.
Although circulating miRNAs have been well studied as biomarkers of various
disease state, the effects of exercise on the circulating microRNA profile are not
completely understood. Current literature shows an effect of acute exercise on the
circulating miRNA profile and it has been suggested that miRNAs play a role in
physiological adaptations to exercise.16, 17 However, less is known about the effects of
exercise training on the circulating miRNA profile. Baggish et al.15 found that 90 days of
rowing significantly altered resting levels of selected circulating miRNAs. Another study
found that 4 weeks of cycling significantly decreased circulating levels of miR-486 and
that this miRNA was correlated with changes in maximal oxygen consumption
V̇O2max.18 Thus, limited evidence of the effects of exercise training on circulating
miRNAs is available. Another limitation of the current literature is that many studies
examine fewer than 10 targeted miRNAs, with little overlap of miRNAs between
studies.17 Taken together, the effects of exercise training on circulating miRNAs are still
largely unclear. Therefore, the purpose of the current study was to examine the effects of
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exercise training on a panel of 84 miRNAs associated with CVD in 20 individuals from
the HERITAGE Family Study. We hypothesized that exercise training would
significantly alter the circulating miRNA profile. We will test these hypotheses with the
following aims:
Aim 1: Determine the effects of endurance exercise training on the abundance of targeted
circulating miRNAs in a subsample of previously sedentary adults from the HERITAGE
Family Study.
We hypothesize that endurance exercise training will significantly alter the circulating
miRNA profile of targeted miRNAs.
Aim 2: Determine the association between circulating miRNA expression levels with
cardiometabolic risk factors at baseline and as an adaptation to exercise training (i.e.,
change score).
We hypothesize that baseline levels and exercise induced changes in circulating miRNAs
will be significantly associated with concomitant levels of lipids and inflammatory
markers.
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CHAPTER 2
A BRIEF HISTORY OF HDL AND MICRORNAS

Cardiovascular disease (CVD) involves the heart or blood vessels and is
associated with multiple physiological and behavioral risk factors including dyslipidemia,
smoking, hypertension, diabetes, and obesity.19 As CVD is the leading cause of death in
the United States20, much of research and resources have focused on the prevention and
treatment of CVD. The association between low high-density lipoprotein cholesterol
(HDL-C) and negative health outcomes was first reported in 1966, when HDL-C levels
were found to be inversely associated with ischemic heart disease risk.21 In 1989 Gordon
et al.22 showed that low levels of high-density lipoprotein cholesterol (HDL-C) was a risk
factor for coronary heart disease. Low HDL-C levels have repeatedly been associated
with increased CVD risk in many different populations across the world.23-26 Similar
results are found in animal models. Overexpression of the human apolipoprotein A-I
(ApoA-I) gene in mice results in an increase in HDL-C concentration that is accompanied
with protection against atherosclerosis.23 Rubin et al.27 found that genetically elevating
ApoA-I and HDL-C concentrations in mice protected against the formation of
atherosclerotic lesions from a high fat diet compared to control mice, demonstrating a
protective effect of HDL-C and ApoA-I. In ApoE deficient mice, who are predisposed to
atherosclerosis, transgenic elevation of HDL-C diminished atherosclerotic lesion
formation and HDL-C levels accounted for 78% of the observed variance in the lesion
4

size.28 This combination of human and animal research led to the hypothesis that elevated
HDL-C levels protects against atherosclerosis and CVD.
The HDL hypothesis has recently been called in to question due to the
ineffectiveness of treatments that raise HDL-C levels to attenuate CVD risk. The 2013
ACC/AHA Guidelines concluded that statins were effective at lowering low density
lipoprotein cholesterol (LDL-C) levels and that these reductions were effective in
reducing CVD risk.29 However, targeted drug treatments for raising HDL-C do not yield
similar results. A meta-analysis by Keene et al.30 of 39 drug trials of niacin, fibrates, and
cholesterol esterase transfer protein (CETP) inhibitors showed that while many of the
trials were successful in raising HDL-C levels, no change in CVD risk was found. In fact,
their meta-analysis showed that despite elevated HDL-C levels some of these drugs were
associated with elevated risk of CVD when compared to control groups.30 Additionally,
mendelian randomization studies have shown that single nucleotide polymorphisms
(SNPs) associated with elevated HDL-C levels are not associated with reduced CVD
risk.31 These studies turned the HDL hypothesis upside down, as HDL-C levels by
themselves do not seem to be protective against CVD. The HDL hypothesis therefore has
recently shifted toward the HDL “function” hypothesis, where the functionality of HDL
particles (HDL-P) is the important factor in determining CVD risk.
Ample evidence exists for a physiological basis of the HDL hypothesis. HDL
plays a critical role in reverse cholesterol transport (RCT), a known anti-atherogenic
function or pathway, by accepting cholesterol on to lipid poor apoA-I, the main protein
constituent of HDL, which is largely mediated by ATP binding cassette transporter A1
(ABCA1).32 HDL also inhibits the expression of endothelial adhesion molecules in vitro33
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and protects against LDL oxidation and apoptosis.34 Finally, HDL can stimulate the
release of nitric oxide from the endothelium and induce vasodilation.35, 36 Perhaps the
most well-established HDL function is the facilitation of RCT. Briefly, HDL and apoA-I
promote cholesterol efflux from peripheral macrophages and other peripheral tissues
primarily through the ABCA1 and ABCG1 transporters.37 Mature, lipid rich, HDL can
then transfer cholesterol to the liver via scavenger receptor class B type 1 (SR-B1) or
indirectly via CETP mediated transfer for excretion.37 Several recent population studies
have shown cholesterol efflux capacity is associated with prevalent and incident of
CVD38-40 and CVD mortality.41 In a prospective study of 2,924 adults from the Dallas
Heart Study, Rohatgi et al.39 found a 67% reduction in atherosclerotic cardiovascular risk
in the highest quartile of cholesterol efflux capacity compared to the lowest quartile after
adjustment for traditional risk factors, HDL-C, and HDL-P concentration. Additionally,
cholesterol efflux capacity of HDL has been reported as independent of traditional
cardiovascular risk, as well as HDL-C and HDL particle concentration.39 Another
atheroprotective function of HDL is the proposed anti-inflammatory properties through
this particle’s ability to inhibit the expression of cell surface adhesion molecules in
endothelial cells.42 HDL has also been reported to inhibit a key enzyme in the production
of endothelial cell adhesion molecules, however this inhibition has a great deal of
variability in humans, likely due to the heterogeneity of HDL molecules themselves.42
The relationship between the anti-inflammatory properties of HDL and CVD risk are still
unclear, but circulating levels of these endothelial cell adhesion molecules (e.g., VCAM1, ICAM-1) are associated with CVD risk.43, 44 Therefore, the connection between HDL
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function and CVD risk goes beyond the role of HDL in RCT and is likely a result of the
combination of all HDL functions.
A recently discovered function or role of HDL is the ability of HDL particles to
transport and deliver microRNAs (miRNAs) to target tissues.1 MiRNAs are small
regulatory RNAs that control gene expression by targeting and binding messenger RNA
(mRNA) and preventing protein production.1, 2 One estimate is that miRNAs account for
1-5% of the human genome and regulate greater than 30% of protein coding genes.2 Over
2,500 different miRNAs have been identified in humans, with more constantly being
discovered.3, 4 As such, circulating miRNA levels may represent a new type of biomarker
for diseases like cancer and CVD.2, 6, 7 The miRNA profile of patients with non-ischemic
systolic heart failure was found significantly altered compared to healthy controls and
correlated with the severity of the heart failure.8 MiRNAs may also be able to predict
cardiovascular events, as Zampetaki et al.10 found that baseline miRNA profiles were
associated with incident myocardial infarction over ten years in an elderly cohort. These
studies illustrate the potential viability of miRNAs as biomarkers of disease and perhaps
even future disease development.
MiRNAs are synthesized in the nucleus and undergo modifications in the
cytoplasm where they form a double stranded duplex before being exported via
exosomes, microvesicles, HDL-P, or in a protein complex.2, 5 The binding of miRNAs to
HDL likely follows a mechanism similar to the binding of small RNAs with liposomes
which means that HDL incorporates the miRNAs into a protected space on the complex.1
Additionally, the HDL-miRNA profile is altered in disease states compared to healthy
controls and compared to circulating exosomal miRNA, potentially representing a
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distinct novel biomarker for disease from circulating miRNA.1, 45 Wagner et al.45 found
similar results showing that HDL-miRNA profiles were altered in patients with acute
coronary syndrome compared to controls, and that three vascular- and inflammatoryrelated miRNAs were most prominent on HDL. Choteau et al.46 examined HDL-miRNAs
in patients with acute coronary syndrome and coronary artery disease (CAD) found that
HDL miR-223 levels were correlated with CAD score (r=0.383, p=0.016) and may reflect
the progression of CAD. In further support of the importance of the HDL-miRNA profile,
Vickers et al.1 found that HDL was effective at delivering miRNAs to target cells.
Hepatocytes were treated with synthesized HDL-miRNA complexes, which led to an
increase in intracellular miRNA and a reduction in the specific miRNA targets.1 This
study also showed that the delivery of HDL-miRNA is SR-B1 dependent, consistent with
the known interaction between HDL and SR-B1 during cholesterol efflux.1 The delivery
of miRNAs by HDL to target cells at least in part mediates the known function of HDL
inhibiting cellular adhesion molecules.47 The discovery of the HDL mediated transport
and functional delivery of miRNAs represents a potential new biomarker for disease and
a target for intervention. Additionally, HDL-miRNAs are an exciting new potential
mechanism by which HDL mediates its antiatherogenic effects.
As discussed above, drug interventions targeted at raising HDL-C levels have not
resulted in improved CVD risk, so alternative therapies for improving HDL function and
cardiovascular health are needed. Regular exercise is an alternate therapy that has been
suggested for reducing CVD risk.48, 49 Regular exercise has favorable effects on both lipid
and lipoprotein profiles50 including increasing plasma HDL-C levels.51 However, the
effects of exercise training on HDL function are still largely unclear. A recent study by
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Khan et al. 2018 found that weight loss combined with exercise in patients with
metabolic syndrome improved HDL composition and cholesterol efflux capacity.52
Recently Sarzynski et al.53 examined the effects of exercise training on HDL mediated
cholesterol efflux capacity across two training studies, and found that only the highest
dose of high intensity exercise resulted in significant changes in global radiolabeled
efflux capacity (+6.2%) in one cohort and non-ABCA1 radiolabeled efflux capacity
(+5.7%) in another cohort. Furthermore, results from the remaining limited literature on
the effects of exercise on HDL mediated cholesterol efflux are mixed. A study in patients
with peripheral artery disease found no effect of exercise training on cholesterol efflux
capacity,54 however this may have been due to the inability of these patients to reach the
intensities necessary to see a change. Koba et al.55 studied patients with acute coronary
syndrome and found that cardiac rehabilitation, even at relatively low intensities,
significantly increased cholesterol efflux capacity compared to baseline but not compared
to controls. Exercise may also impact the anti-inflammatory properties of HDL. A shortterm diet and exercise intervention was effective at converting pro-inflammatory HDL to
anti-inflammatory in overweight and obese men.56 Some evidence does exist for a
beneficial effect of exercise on the anti-oxidative properties of HDL. In patients with type
II diabetes, four months of endurance training improved the ability of HDL to inhibit
LDL oxidation, but this improvement was not seen in the healthy control group.57
However, the effects of exercise on the anti-inflammatory and anti-oxidative properties
are still largely unclear, as there are limited studies and most of the beneficial effects of
exercise on HDL function have been found in studies examining diseased populations.
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While the effects of exercise on HDL function are somewhat unclear, ample
evidence exists of an effect of exercise on circulating miRNA levels. In 32 healthy
trained men, acute endurance exercise up regulated selected miRNAs one to three hours
after the last exercise session, and basal levels of nine selected miRNAs were
significantly altered following 12 weeks of endurance training.58 The authors proposed
that a mechanism for the alteration of circulating miRNAs following training is the
associated/concomitant alteration of lipoprotein levels.58 Xu T et al.5 in a recent review
speculated that the rise in circulating miRNAs following acute exercise may be due to
muscle damage and subsequent release of miRNAs from damaged tissue. The authors
also noted that the effects of chronic exercise on circulating miRNAs are still unclear, as
some miRNAs seem to be upregulated following chronic exercise while others are down
regulated.5 The fact that miRNA levels themselves change with exercise has significant
implications for disease and may mediate some of the beneficial effects of exercise.59
Uhlemann et al.60 showed that endurance training acutely increases endothelial specific
miRNA and resistance training increased skeletal muscle specific miRNA.
Despite numerous studies examining changes in circulating miRNAs with
exercise, to our knowledge no study has examined the effects of exercise on HDLmiRNAs. Additionally, most of the research on the effects of exercise on circulating
miRNAs has examined the acute effects of exercise.16 Thus, a need exists for further
research concerning the effects of exercise training on circulating miRNAs in different
populations.
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CHAPTER 3
METHODOLOGY

HERITAGE Family Study. The HERITAGE Family Study (hereafter referred to as
HERITAGE) is one of the largest, most well-controlled, standardized exercise training
studies to date. HERITAGE was designed to examine the role of genetic factors on
cardiometabolic responses to endurance exercise training. The HERITAGE cohort is
composed of 481 whites (232 men and 249 women) from 99 families and 250 blacks (88
men and 162 women) from 105 family units that completed a 20-week endurance
exercise program at one of four clinical centers (Indiana, Minnesota, Québec, Texas). The
study design and training protocol have been described in detail elsewhere.61 Briefly, the
participants were sedentary at baseline, normotensive or mildly hypertensive (<160/100
mm Hg) without medications for hypertension, diabetes, or dyslipidemia.
Exercise training program. The training program consisted of three weekly
sessions of cycling at the heart rate associated with 55% of baseline VO2max for 30
minutes for the first two weeks. The duration and intensity were then gradually increased
every two weeks until the heart rate associated with 75% of baseline VO2max for 50
minutes was achieved. This level was maintained for the final six weeks of training. All
training was performed on Universal Aerobicycles (Cedar Rapids, IA). Power output was
controlled directly relative to heart rate by using the Universal Gym Mednet (Cedar
Rapids, IA) computerized system. The protocol was standardized across all clinical
11

centers and supervised to ensure that the equipment was working properly and that the
participants were compliant with the protocol.
Exercise tests. Three exercise tests were administered prior to training and three
additional tests were given at the end of training. All tests were completed on a stationary
cycle ergometer. The first test at each time point was used to establish the participants
V̇O2max. During the second test of each battery, participants cycled at 50 watts and 60%
of their V̇O2max for 8 minutes each. The third and final test of each battery consisted
again of 8 minutes each of 50 watts and 60% V̇O2max, after which the power output was
increased to 80% V̇O2max for three minutes, and continually increased until exhaustion.
During the third test blood was collected via a venous catheter. 61
Subjects for current study. Twenty white subjects from HERITAGE that
completed the 20-week exercise program were selected for this study based on
discordance for exercise-induced changes in HDL particle size. All subjects selected for
this exploratory study were from the Québec center, as the Québec participants were also
part of an ancillary study that involved skeletal muscle biopsies and have available gene
expression data.
Blood collection. Blood samples were obtained from an antecubital vein into
sealed Vacutainer tubes in the morning after a 12-hour fast with participants in a semirecumbent position. The blood samples were collected at baseline and again at 24 hours
after the last training session. Blood samples were allowed to clot at room temperature
and serum was separated via centrifugation according to standard methods. For
eumenorrheic women, all samples were obtained in the early follicular phase of the
menstrual cycle when blood plasma cholesterol alterations are minimal.61
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HDL isolation. HDL isolation was previously performed on these 20 subjects
using the following procedures. HDL plasma was separated from whole serum via fast
performance liquid chromatography (FPLC) with size exclusion chromatography.
Briefly, 370 µL of whole serum was injected into an Akta Pure FPLC and run through
two gel filtration columns (Superdex 200 increase columns, GE Healthcare). HDL
fractions were collected and pooled together then aliquoted for storage in a -80°C freezer.
HDL plasma was then concentrated by adding 500 µL of plasma HDL to an Amicon
Ultra 0.5 mL centrifugal filter with a 3000 dalton cellulose membrane in a 2 mL
centrifuge tube and spinning at 14,000 x g for 30 minutes at room temperature. The flow
through was discarded and the filter device removed and placed upside down in a clean
tube and spun at 1,000 x g for 2 minutes at room temperature, yielding approximately 60
µL of concentrated HDL serum.
Note: The miRNA PCR analysis of serum HDL samples was largely
unsuccessful, therefore for the remainder of the document, analysis will focus on
circulating miRNAs.
MiRNA analysis. MiRNAs were extracted on the QIAcube workstation from
baseline and post-training whole serum samples using miRNeasy Serum/Plasma
Advanced Kits (Qiagen, Hilden, Germany). Samples were spiked with a known amount
of synthetic C. elegans miR-39-3p. MiRNA quantification was then performed using
reverse transcriptase real-time polymerase chain reaction (RT-qPCR). Briefly, cDNA was
transcribed from the extracted miRNA and then aliquoted into the Human Cardiovascular
Disease miScript miRNA PCR Array (Qiagen, Hilden, Germany). This array contains
primers for 84 miRNA sequences identified as exhibiting altered expression during CVD
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and development. The selected miRNAs are listed in Table 3.1. All cDNA steps and PCR
setup were performed by the QIAgility instrument (Qiagen, Hilden, Germany) using an
automated pipetting protocol. Real-time qPCR was performed on the miRNA PCR array
in the Rotor-Disc 100 format by the Rotor-Gene Q real-time PCR cycler (Qiagen, Hilden,
Germany). Rotor-Gene PCR cycling conditions were performed according to
manufacturer’s suggested protocol and conditions.
Cardiometabolic trait measurement. Total cholesterol and triglyceride levels in
plasma and lipoproteins were measured by enzymatic methods using the Technicon RA1000 analyzer.61 Lipoprotein subclass and particle size measurements were performed
using NMR spectroscopy previously described.62 Substrate utilization and ventilation
during submaximal exercise were measured via standard methods previously described.61
Statistical methods. The effect of training on circulating miRNAs (Aim 1) was
assessed using paired t-tests of pre- and post-training miRNA levels. Cycle threshold (Ct)
represents the cycle number at which there is an exponential increase in miRNA
fluorescence. Delta Ct was calculated by subtracting the global geometric mean signal of
all detected miRNAs from individual Ct values. Delta delta Ct was then calculated by
subtracting delta Ct values of baseline samples from delta Ct values post-training. Fold
change was calculated as 2-∆∆Ct using the global geometric mean signal of all detected
microRNAs as the normalizer value. Pearson’s correlations were used to examine the
associations between baseline and fold change in miRNA levels with change in select
cardiometabolic phenotypes(Aim 2). All analyses were performed using SAS 9.4 (Cary,
NC).
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Table 3.1. List of miRNAs included on Qiagen’s Human Cardiovascular Disease
miScript miRNA PCR Array.
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CHAPTER 4
RESULTS

Baseline characteristics including mean values for the standard lipid panel and
other cardiovascular risk factors are shown in Table 4.1. No significant differences were
found between sexes. The expression levels of five miRNAs were nominally (p<0.05)
down regulated with exercise. Exercise resulted in a fold change of 0.82 (p=0.04) for mir155-5p, 0.49 (p=0.01) for let-7b-5p, 0.70 (p=0.04) for let-7e-5p, 0.56 (p=0.02) for miR486-5p, and 0.42 (p=0.01) for miR-7-5p, all compared to baseline expression levels. In
addition to fold change, average Ct values increased in all five miRNAs (Figure 4.1),
indicating reduced expression following exercise. Change in miR-486-5p expression was
moderately correlated with change in small high-density lipoprotein (HDL) particle
concentration (r=-0.55, p=0.01) and change in low-density lipoprotein (LDL) particle size
(r=0.53, p=0.01). Additionally, change in miR-7-5p was correlated with change in very
low-density lipoprotein (VLDL) particle concentrations (r=-0.47, p=0.04). Fold change of
miR-155-5p and let-73-5p were correlated with change in plasma free fatty acids at 50W
and 60% of max workload, as well as change in circulating glucose at 60% max workload
(Table 4.2).
Baseline levels of numerous miRNAs were nominally (p<0.05) correlated with
changes in cardiometabolic traits following exercise training. Baseline expression levels
of miR-124-3p, miR-143-3p, and miR-199a-5p were moderately positively correlated
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with changes in V̇O2max (r=0.48-0.54, p=0.02-0.04). Expression levels of 24 circulating
miRNAs at baseline were positively correlated with change in plasma apoA-1 levels
(range: r=0.47-0.64, p=0.003-0.04) (Table 4.3). Baseline levels of 12 different miRNAs
were correlated with exercise induced changes in HDL cholesterol levels (Table 4.4), and
baseline expression levels of 7 different miRNAs were correlated with change in mean
arterial pressure with exercise (Table 4.5). The baseline miRNA expression level of 51
miRNAs were negatively correlated with change in end tidal carbon dioxide pressure
(PETCO2) during submaximal exercise (range: r=-0.49 to -0.81, p<0.0001-0.01). These
51 miRNAs are listed in Table 4.6.
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Table 4.1. Participant baseline characteristics given as means (standard deviation).
Age (years)
BMI (kg/m2)
VO2 max (L/min)
HDL-C (mg/dL)
LDL-C (mg/dL)
TC (mg/dL)
TG (mg/dL)
CRP (mg/dL)
SBP (mmHg)
DBP (mmHg)
Waist (cm)
Percent fat

(n=20)
43.4 (13.1)
26.4 (3.7)
2.1 (0.5)
43.4 (10.7)
134.4 (34.3)
203.7 (37.5)
159.1 (84.3)
0.29 (0.3)
116.7 (12.8)
65.9 (9.9)
90.5 (11.6)
28.9 (6.9)

BMI: body mass index, HDL-C: high-density lipoprotein cholesterol, LDL-C: lowdensity lipoprotein cholesterol, TC: total cholesterol, TG: triglycerides, CRP: C-reactive
protein, SBP: systolic blood pressure, DBP: diastolic blood pressure,
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Figure 4.1. Baseline and post-training cycle threshold (CT) values along with individual
exercise response for miRs: let-7b-5p let-7e-5p, miR-155-5p, miR-486-5p, and miR-7-5p.
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Table 4.2. Correlation between fold-change in select miRNAs and concomitant change in
substrate utilization
miR-155-5p
Let-7b-5p
Let-7e-5p
miR-486-5p
miR-7-5p

FFA 50W

FFA 60%

Glucose 60%

Aldosterone

0.73
NS
0.72
NS
NS

0.59
NS
0.60
NS
NS

0.49
NS
0.53
NS
NS

NS
0.61
NS
NS
0.58

All correlations listed were p<0.05. NS, not significant (p>0.05). FFA 50W: free fatty
acids at 50 watts workload, FFA 60%: free fatty acids at 60% workload, Glucose 60%:
glucose at 60% workload
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Table 4.3. Correlation between baseline miRNA expression and change in apoA-1.
Let-7c-5p
Let-7d-5p
miR-10b-5p
miR-130a-3p
miR-140-5p
miR-142-3p
miR-150-5p
miR-16-5p
miR-195-5p
miR-221-3p
miR-222-3p
miR-24-3p
miR-25-3p
miR-26a-5p
miR-29a-3p
miR-29b-3p
miR-30a-5p
miR-30c-5p
miR-30e-5p
miR-320a
miR-342-3p
miR-451a
miR-93-5p
miR-99a-5p

r

p-value

0.64
0.47
0.53
0.48
0.47
0.47
0.47
0.50
0.53
0.55
0.57
0.48
0.53
0.49
0.49
0.53
0.55
0.52
0.59
0.55
0.54
0.52
0.59
0.49

0.003
0.04
0.02
0.04
0.04
0.04
0.04
0.03
0.02
0.01
0.01
0.04
0.02
0.03
0.03
0.02
0.01
0.02
0.01
0.01
0.02
0.02
0.01
0.03
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Table 4.4. Correlation between baseline miRNA expression levels and change in HDL-C
levels
Let-7a-5p
Let-7c-5p
miR-130a-3p
miR-17-5p
mir-185-5p
miR-195-5p
miR-223-3p
miR-23b-5p
miR-31-5p
miR-320a
miR-98-5p
miR-99a-5p

r

p-value

0.51
0.50
0.52
0.48
0.50
0.54
0.49
0.53
-0.46
0.49
0.49
0.47

0.03
0.03
0.02
0.04
0.03
0.02
0.03
0.02
0.04
0.03
0.03
0.04
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Table 4.5. Correlation between baseline miRNA expression levels and change in mean
arterial pressure.
Let-7a-5p
Let-7c
Let-7f-5p
miR-210
miR-26b-5p
miR-98-5p
miR-99a-5p

r

p-value

-0.59
-0.54
-0.49
-0.49
-0.57
-0.50
-0.61

0.01
0.02
0.03
0.03
0.01
0.03
0.01
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Table 4.6. List of baseline miRNAs significantly correlated with change in PETCO2
during submaximal exercise

Let-7c
miR-130a-3p
miR-15b-5p
miR-195-5p
miR-223-3p
miR-26b-5p
miR-30a-5p

Let-7d-5p
miR-140-5p
miR-16-5p
miR-199a-5p
miR-224-3p
miR-27a-3p
miR-30c-5p

miR-103a-3p
miR-143-3p
miR-17-5p
miR-21-5p
miR-23a-3p
miR-27b-3p
miR-30d-5p

miR-124-3p
miR-144-3p
miR-181b-5p
miR-210
miR-24-3p
miR-29a-3p
miR-30e-5p

miR-125a-5p
miR-145-5p
miR-185-5p
miR-214-3p
miR-25-3p
miR-29b-3p
miR-320a

miR-126-3p
miR-146a-5p
miR-18b-5p
miR-221-3p
miR-26a-5p
miR-29c-3p
miR-342-3p

miR-365a-3p

miR-423-3p

miR-424-5p

miR-451a

miR-494

miR-92a-3p

miR-93-5p

miR-98-5p

miR-9a-5p
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CHAPTER 5
DISCUSSION

Exercise training nominally down-regulated 5 miRNAs related to cardiovascular
disease compared to baseline in 20 healthy, previously sedentary adults from the
HERITAGE Family Study. Exercise induced changes in miRNA expression levels were
correlated with concomitant changes in select cardiometabolic factors such as HDL-C
and plasma free fatty acids during submaximal exercise.
The down regulation of the five miRNAs in the current study could be explained
by a few different mechanisms. One would be a degradation of the miRNAs in
circulation with exercise, however miRNAs are transported within vesicles or within
protein complexes that prevent degradation,1, 2 so this seems unlikely. Exercise could also
influence the expression of the miRNAs themselves, however little is known about
potential mechanism(s) by which exercise could accomplish this. MiRNA expression can
certainly be regulated and altered, but the regulation of miRNA is complex and not fully
understood.63 Another potential mechanism would be the promotion of selective uptake
of these miRNAs by skeletal muscle with exercise. Several studies have demonstrated the
ability of target cells, such as skeletal muscle, to take up circulating miRNAs.1, 2, 64 One
plausible explanation is that the reduction of these five miRNAs in circulation with
exercise training may in part be due to increased uptake of these miRNAs by skeletal
muscle. Exercise training however does not likely increase the uptake of all miRNAs by
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skeletal muscle and may in fact increase the release of certain miRNAs into circulation.
Baggish et al.15 found that exercise training resulted in an up-regulation of miR-222,
miR-21, and miR-221. Interestingly these same three miRNAs were also up-regulated
following acute exercise, indicating a potential additive effect of acute bouts with training
that serves to upregulate certain miRNAs.15
The current study found that exercise training down-regulated miR-486-5p.
Similarly, in a study of 11 healthy young men both a single cycling exercise session and
four weeks of exercise training significantly decreased circulating levels of miR-4865p.18 Additionally, the directionality of the change in circulating miR-486-5p with
exercise was the same following an acute bout and following exercise training,18 giving
further evidence for an additive effect of acute bouts that may lead to a training effect.
MiR-486-5p targets phosphatase and tensin homolog (PTEN), a negative regulator of Akt
signaling, and therefore increases insulin-dependent glucose uptake.65 It is well
established that exercise training improves insulin dependent glucose uptake in skeletal
muscle.66, 67 Therefore, the reduction of circulating miR-486-5p may be the result of an
increased uptake of the miRNA into the skeletal muscle. This uptake of miR-486-5p may
in turn be responsible for improvements in insulin dependent glucose uptake by the
skeletal muscle following exercise training.
MiR-155-5p is down regulated in mice following 12 weeks of endurance exercise
training.68 Data from this study supports the current study’s finding that exercise training
down regulates circulating miR-155-5p. MiR-155-5p is drastically upregulated in
atherosclerosis, and miR-155-5p targets eNOS and inhibits nitric oxide production.69, 70
MiR-155-5p expression also promotes cardiac inflammation and failure in mice.71 Bone
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marrow transplant into miR-155-5p knockout mice was effective at rescuing the cardiac
hypertrophy, demonstrating the importance of reducing miR-155-5p expression even in a
diseased state.71 The physiological role of miR-155-5p with atherosclerosis and heart
failure highlights the potential clinical importance of strategies that reduce circulating
levels of this miRNA. Further research is needed to determine if the reduction in
circulating miR-155-5p is associated with a similar reduction in vascular miR-155-5p.
Little is known about the effects of exercise on the let-7 family of miRNAs, and
this study may be the first to show a down regulation of let-7b and let-7e following
exercise training. This reduction may be beneficial as plasma levels of let-7b are elevated
during an ischemic stroke and has been identified as a potential biomarker of stroke.72
However, the physiological basis for this increase is unclear. The let-7 family of miRNAs
has been implicated in both the immune and inflammatory response.73, 74 Let-7e has been
identified as a pro-inflammatory miRNA and may play a role in atherosclerosis.73
Therefore, the reduction of circulating levels of let-7b and let-7e with exercise may have
clinical relevance for a reduction in inflammation.
Baggish et al.15 reported that exercise training significantly altered the expression
of select miRNAs and that this alteration was associated with changes in V̇O2max,
indicating a potential role of miRNAs as mediators of exercise induced cardiovascular
and metabolic adaptations. Similarly, we found that baseline expression levels of three
miRNAs were moderately positively correlated with exercise-associated changes in
V̇O2max, further implicating miRNAs in response of V̇O2max to training. The current
study found that change in circulating miR-486-5p was correlated with changes in size of
both HDL particles and LDL particles. MiR-486 has been reported to associated with
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HDL2 (large HDL) but not HDL3 (small HDL),75 suggesting a relationship between miR486 and lipoprotein size. Additionally, changes in miR-155-5p and let-7e-5p were
correlated with change in circulating free fatty acids and plasma glucose during
submaximal exercise. Both circulating free fatty acids and plasma glucose are measures
of substrate utilization during exercise. Exercise training improves the utilization of lipids
during moderate intensity exercise.76 An increase in circulating free fatty acids during
exercise may indicate greater mobilization of fats for use and may represent a shift
toward lipid metabolism. This increase in circulating free fatty acids is expected near the
end of an acute bout of moderate exercise as substrate utilization shifts toward lipids,77
therefore an increase in circulating free fatty acids during submaximal exercise following
training may indicate improved lipid metabolism following training. Thus, the change in
select circulating miRNAs may mediate metabolic changes observed during submaximal
exercise following exercise training.
This study also examined associations between the baseline miRNA profile and
changes in cardiometabolic risk factors. Baseline levels of several miRNAs were
positively correlated with change in HDL-C levels and change in apoA-1 levels. As
discussed previously, HDL-C has long been used as a biomarker for cardiovascular
health,21 however focus has recently shifted to the functionality of HDL instead of HDLC levels. ApoA-1 is the primary functional protein of HDL and has been inversely
associated with a reduction in risk of atherosclerosis.27 The potential ability of miRNAs
to predict response of both HDL-C and apoA-1 levels to exercise training would allow
for the tailoring of exercise prescriptions for individuals with low HDL-C or apoA-1
levels. Strikingly, over 50 baseline miRNAs were negatively correlated with change in
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PETCO2 during submaximal exercise at 60% VO2max. PETCO2 decreases as a result of
decreased pulmonary blood flow and decreased cardiac output and is a surrogate measure
for tolerance to exercise.78, 79 PETCO2 is decreased in patients with chronic obstructive
pulmonary disease, indicative of diminished exercise tolerance.79 Therefore an increase in
PETCO2 during submaximal exercise following training is indicative of an improved
ventilatory tolerance to exercise. The current results suggest that the circulating miRNA
profile at baseline may be able to predict the response of PETCO2 during acute exercise
to exercise training.
Our study benefitted from the use of a miRNA PCR array that included 84
miRNAs associated with cardiovascular disease and development. However, the
relatively small and heterogeneous sample may not be representative of other
populations. Additionally, this was the first study to examine the effects of exercise for
many of the included miRNAs, thus further research is needed to confirm our findings.
Further research is also needed to determine the mechanisms by which exercise alters
circulating miRNA expression and the association of changes in the circulating miRNA
profile with changes in clinical outcomes.
Exercise training may alter the circulating miRNA profile of select cardiovascular
disease related miRNAs and these alterations may have physiologically significant roles.
The reduction in select miRNAs with exercise may be clinically significant given the
diverse role of these miRNAs in disease development. The current study provides further
support for the effects of exercise training on circulating miRNAs such as miR-486 and
miR-155 and gives new evidence miR-7 and miRNAs in the let-7 family. Additionally,
the current study provides preliminary evidence for the use of circulating miRNAs as
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biomarkers for exercise training efficacy and predicting exercise training response, which
may be useful in clinical exercise prescription. Future research is needed on the effects of
exercise on the untargeted circulating miRNA profile to identify novel miRNAs
associated with exercise and confirm the existing findings.
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